Acetaminophen Dose Reduction Public Health Damage Cited By McNeil
This article was originally published in The Tan Sheet
Executive Summary
Lowering the highest approved OTC acetaminophen dose would result in pain relief that is "inadequate or of limited duration for many individuals," McNeil Consumer & Specialty Pharmaceuticals tells FDA's Nonprescription Drugs Advisory Committee
You may also be interested in...
Acetaminophen GI Label Warnings Justified By Recent Data, Bayer Contends
Acetaminophen products should be required to carry gastrointestinal warnings similar to those on aspirin labeling, Bayer Consumer Care asserts
Voluntary Acetaminophen Labeling Revisions Include Overdose Warning
McNeil Consumer & Specialty Pharmaceuticals and Bayer Consumer Care are revising acetaminophen product labeling to add a distinct "overdose warning," the companies say in materials submitted to FDA's Nonprescription Drugs Advisory Committee
Most Acetaminophen Pediatric AERs Due To Medication Errors, FDA Asserts
Exceeding the recommended daily dose of acetaminophen resulted in hepatotoxic adverse events more often than use at or below recommended amounts, FDA says in 1briefing documents for the Nonprescription Drugs Advisory Committee meeting on analgesic safety Sept. 19-20